报价延迟最少15分钟:2025/07/21 11:06 EDT
常规时段
|
|
|
|
|
||||||||||||
|
|
|
|
|
8.4 
|
|
|
| 价值评估 |
|
盈利(现时/预测)
-5.59/-3.61
|
|
企业价值
191.64M
|
| 资产负债 |
|
每股账面净值
7.52
|
| 现金流量 |
|
现金流量率
--
|
| 损益表 |
|
收益
0
|
|
每股收益
--
|
|
同行比较
|
||||||||||||||||||||||||||||||||||||||||||||||||
|
报价延迟最少15分钟：2025/07/21 11:06 EDT
同行比较之报价最少15分钟延迟
|
业务概览
|
|||
| Cybin Inc is a biopharmaceutical company involved in creating safe and effective therapeutics for patients to address a multitude of mental health issues. The Company is a clinical-stage neuropsychiatric company focused on advancing therapies, delivery mechanisms, novel compounds, and protocols as potential treatments for various psychiatric and neurological conditions. The Company is developing technologies and delivery systems aimed at improving the pharmacokinetics of itsproprietary molecules while retaining the therapeutic benefit. These new molecules and delivery systems are expected to be studied through clinical trials to confirm safety and efficacy. |
